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 ABSTRACT 
Hypoxia in tumors has been found to decrease the effectiveness of cancer 
treatment; in particular, it can diminish the effect of radiation therapy. Furthermore, 
hypoxia has been associated with malignant progression and metastatic disease. Patients 
with hypoxic tumors may thus benefit from a more aggressive treatment. A noninvasive 
diagnostic method for detecting these tumors is therefore urgently needed.  
In this thesis, the potential usefulness of dynamic Gd-DTPA-enhanced MRI for 
assessing tumor hypoxia, radiation response, and metastatic potential has been evaluated 
preclinically. The DCE-MRI series were analyzed by using one of the most widely known 
pharmacokinetic models, the generalized kinetic model of Tofts. Human melanoma 
xenografts and cervical carcinoma xenografts were used as tumor models in the study. 
The DCE-MRI-derived parameters Ktrans and ve were shown to be able to distinguish 
between tumors with and without hypoxia, as well as to give information about the extent 
of tumor hypoxia. Furthermore, it was demonstrated that Ktrans is able to predict radiation 
response. Finally, both Ktrans and ve showed the ability to predict metastatic potential. In 
conclusion, this preclinical study demonstrates the potential of the DCE-MRI-derived 
parameters Ktrans and ve as predictive markers, warranting further clinical studies.  
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AIMS OF THE STUDY 
Approximately 50 years ago, Thomlinson and Gray proposed that there were 
regions of low levels of oxygen, hypoxic tissue, in human tumors (Thomlinson and Gray, 
1955). More recent clinical investigations have revealed that there are hypoxic regions in 
a wide range of malignancies, including: cancers of the breast, uterine cervix, vulva, head 
and neck, prostate, rectum, pancreas, and lung, and also brain tumors, soft tissue 
sarcomas, non-Hodgkin’s lymphomas, malignant melanomas, metastatic liver tumors, and 
renal cancer (Vaupel and Mayer, 2007; Wouters et al., 2002). Clinical studies have shown 
that tumor hypoxia is a prognostic marker independent of other prognostic factors such as 
tumor stage and nodal status (Vaupel and Mayer, 2007). Additionally, tumor hypoxia 
may cause resistance to treatment and promote metastatic spread (Wouters et al., 2002). 
Patients with extensive hypoxic tumors may therefore benefit from receiving a 
particularly aggressive treatment. A noninvasive method for identifying these patients is 
therefore urgently needed. 
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a 
noninvasive imaging technique that is currently being used in oncology for cancer 
detection, staging, diagnosis, and assessment of treatment response (Hylton, 2006; Zahra 
et al., 2007). Several studies have found correlations between DCE-MRI-derived 
parameters and known prognostic factors such as histological grade, lymph node status, 
and presence of metastatic disease (Hylton, 2006). Studies have also suggested that DCE-
MRI may provide useful prognostic information for cancer patients receiving 
radiotherapy (Zahra et al., 2007). Additionally, clinical studies have suggested that valid 
information about the hypoxic status of the tumor can be obtained by DCE-MRI (Cooper 
et al., 2000; Newbold et al., 2009).  
The potential of gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA)-
based DCE-MRI-derived parameters as biomarkers for particularly aggressive tumors is 
currently being investigated in our laboratory by using human tumor xenografts as 
preclinical models of human cancer. The advantage of preclinical studies is that the 
experimental conditions can be controlled more easily than in clinical experiments. 
Furthermore, preclinical studies allow a range of experiments that is not possible in a 
clinical study. This makes it possible to compare detailed biological data with DCE-MRI 
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data. Several studies in our laboratory have investigated the potential of DCE-MRI in 
assessing the physiological microenvironment in tumors (Egeland et al., 2012; Gulliksrud 
et al., 2009; Vestvik et al., 2007). Our laboratory has especially focused on the potential 
that DCE-MRI might have in assessing hypoxia, and these studies have in most cases 
used intradermally implanted melanomas as tumor models (Egeland et al., 2008; Egeland 
et al., 2009; Egeland et al., 2012; Vestvik et al., 2007). In the current work, investigation 
of the potential of DCE-MRI as a biomarker for hypoxia was extended to include 
intramuscularly implanted melanomas. Additionally, the ability of DCE-MRI to predict 
response to fractionated radiation treatment was evaluated. Finally, emphasis was placed 
on the potential that DCE-MRI may have as a biomarker for metastatic disease.  
 
The specific aims of the present work were:  
To investigate the potential usefulness of DCE-MRI as a biomarker for: 
• Hypoxia 
• Response to radiation therapy 
• Metastatic potential 
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INTRODUCTION 
Tumor physiology 
Angiogenesis 
Angiogenesis í the formation of new vessels í is governed in both normal and 
neoplastic tissue by the net balance between pro- and antiangiogenic factors (Carmeliet 
and Jain, 2000). For clusters of cells to grow beyond a certain size (1-2 mm in diameter), 
a vasculature is needed to provide nutrients and oxygen. Consequently, angiogenesis is 
one of the hallmarks of cancer, being a necessity for further growth of all solid tumors 
(Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). The cellular aggregates 
may, however, enter a dormant phase for many years if the angiogenic process fails. Such 
dormant cellular aggregates are often referred to as tumor in situ and may remain dormant 
indefinitely (Folkman and Kalluri, 2004). The angiogenic switch can be turned on at any 
time, and when the angiogenesis is initiated, tumor growth, malignant progression, and 
metastatic dissemination may follow. In malignant tumors, the angiogenic process is out 
of control due to an imbalance between pro- and antiangiogenic factors, as illustrated in 
Figure 1b (Jain and Stylianopoulos, 2010). The balance between pro- and antiangiogenic 
factors is strictly controlled in normal tissue, and angiogenesis only occurs under special 
conditions such as embryonic development and wound healing. Pro- and antiangiogenic 
factors can originate from cancer cells, endothelial cells, stromal cells, blood, or the 
extracellular matrix (Carmeliet and Jain, 2000). Well-known proangiogenic factors 
include fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), 
interleukin 8 (IL-8), and platelet-derived growth factor (PDGF). Examples of 
antiangiogenic factors include thrombospondin, tumstatin, canstatin, endostatin, 
angiostatin, and interferon alpha/beta (Folkman and Kalluri, 2004).  
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Figure 1: Angiogenesis is controlled by pro- and antiangiogenic factors. In tumors, there is an 
imbalance between pro- and antiangiogenic factors, causing an abnormal angiogenic process, 
which again leads to a chaotic vascular structure. a) Balance between pro- and antiangiogenic 
factors, resulting in a normal vasculature. b) Imbalance between pro- and the antiangiogenic 
factors, resulting in an abnormal vascular structure. The figure is reproduced from Jain and 
Stylianopoulos (2010). 
 
In normal tissue, there are three different modes of vessel formation, whereas in 
neoplastic tissue there are six. These six modes of vessel formation are illustrated in 
Figure 2. The modes of vessel formation that can occur in normal tissue are: 
• Sprouting angiogenesis; endothelial cells (ECs) in a preexisting blood vessel 
escape from the parent vessel wall into the surrounding matrix and form solid 
sprouts connecting neighboring vessels. Unlike all the other vessel formation 
mechanisms, sprouting angiogenesis creates entirely new vessels. (Fig. 2a) 
• Vasculogenesis; angioblasts differentiate into ECs that assemble into a vascular 
labyrinth. (Fig. 2b) 
• Intussusception; preexisting vessels split and give rise to new vessels. (Fig. 2c)  
In tumors, the additional following modes of vessel formation may occur: 
• Vessel co-option; tumor cells “hijack” the preexisting vasculature. (Fig. 2d) 
• Vascular mimicry; tumor cells line existing vessels, mimicking ECs. (Fig. 2e) 
• Tumor cell ĺ EC differentiation; putative cancer stem-like cells create the tumor 
endothelium (Fig. 2f). This way of vessel formation is, however, much disputed.  
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Figure 2: Modes of vessel formation. Sprouting angiogenesis a), vasculogenesis b), 
intussusception c), vessel co-option d), vascular mimicry e), cancer stem-like cells differentiate 
into ECs f). a-c can occur in both normal and neoplastic tissue, while d-f only occur in neoplastic 
tissue. The figure is reproduced from Carmeliet and Jain (2011).  
 
Angiogenic activity is not necessarily correlated with tumor aggressiveness for all 
tumor types (Bergers and Benjamin, 2003). Nevertheless, the resulting abnormal 
vasculature may contribute to malignant progression and prevent chemotherapy from 
reaching the tumor cells (Jain, 2008). In 1971, Judah Folkman proposed that 
antiangiogenic drugs might be used to starve the tumor, thereby stopping the tumor’s 
growth (Folkman, 1972). Since then, there has been an increased focus on antiangiogenic 
therapy, and today antiangiogenic drugs have been approved for clinical use for several 
types of cancer. 
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Vasculature and blood flow 
The uncontrolled angiogenic process in tumors results in a disorganized tumor 
vasculature. Some of the differences between the vasculature in normal tissue and tumor 
tissue are shown in Figure 3. Unlike the vasculature in normal tissue, the vasculature in 
tumor tissue may lack a hierarchical structure and show severe architectural 
abnormalities. Tumor vessels are irregularly shaped, tortuous, elongated, dilated and may 
have dead ends (Bergers and Benjamin, 2003; Vaupel et al., 1989). They may share 
chaotic features from arterioles, capillaries and venules instead of being strictly defined 
(Bergers and Benjamin, 2003). Additionally, the microvascular density (MVD) within the 
tumor also differs to a larger degree than in normal tissue (Gillies et al., 1999).  
 
 
Figure 3: Images of the colorectal vasculature in normal mucosa a, b) and carcinoma c, d). In the 
normal mucosa, the vasculature is highly organized, whereas the vessels in the tumor are 
heterogeneously distributed, the vessel diameters vary (arrows), and there are dead ends (circles). 
The figure is reproduced from Konerding et al. (2001).  
 
Moreover, the vessel walls in tumors may have incomplete or missing endothelial 
lining, interrupted or absent basement membrane, blood channels lined by tumor cell 
cords, and they may lack pericytes (Vaupel et al., 1989). As a result of these 
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abnormalities, tumor blood vessels may become more permeable than vessels in normal 
tissue. The vascular permeability can vary both within and among tumors (Tredan et al., 
2007).  
The abnormal morphology of the tumor vasculature combined with a decrease in 
vessel density may generate geometric resistance to blood flow, which in turn can lead to 
lower perfusion (Vaupel, 2004). The blood flow can be heterogeneous, with both highly 
perfused areas and areas that have little or no perfusion within the tumor (Vaupel et al., 
1989). However, the variability in tumor blood flow seems to be greater between tumors 
than within a tumor (Vaupel, 2004). The low and heterogeneous blood perfusion in 
tumors may result in an inadequate supply of oxygen and nutrients in tumor regions.  
Hypoxia 
The oxygen level in cells is determined by the demand for and supply of oxygen 
to the cells (Gulledge and Dewhirst, 1996). The demand for oxygen by cells is determined 
by their cellular respiration. Moreover, the cell density in a specific area also has an 
impact on the total demand for oxygen in that area. The supply of oxygen is determined 
by the proximity of the cells to the vasculature, the amount of oxygen in the blood, and 
the blood flow. The demand for oxygen in tumors is not always met by the supply, 
resulting in tumor hypoxia. The demand for, and supply of, oxygen can vary within 
tumors, leading to heterogeneous oxygen levels within individual tumors (Wouters et al., 
2002).  
Generally, tumor hypoxia is divided into two categories based on the cause and/or 
duration of the low levels of oxygen. Chronic hypoxic cells are cells located outside the 
diffusion limit of oxygen, approximately 150 ȝm from a functional blood vessel. These 
cells are also referred to as diffusion-limited hypoxic cells. They will be chronically 
hypoxic since oxygen rarely reaches them through diffusion. Necrotic cells are often 
located next to chronically hypoxic cells. Acutely hypoxic cells are cells that are exposed 
to low levels of oxygen during a short period of time, often no more than a few minutes. 
These cells may, for instance, be located next to a transiently occluded vessel; acute 
hypoxia is, therefore, often referred to as transient hypoxia (Vaupel and Mayer, 2007). If 
the same tumor cells are repeatedly exposed to hypoxia, the term ‘cyclic hypoxia’ is often 
used about these acutely hypoxic cells. The two types of hypoxia are illustrated in Figure 
4.  
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Figure 4: Schematic illustration of chronic and acute hypoxia. To the left: a functional blood 
vessel and chronic hypoxic cells located outside the diffusion limit of oxygen. To the right: a 
temporarily occluded blood vessel, hence acute hypoxia in the cells adjacent to the blood vessel. 
The figure is reproduced from Horsman (1998). 
 
Normal oxygen levels vary in different organs; consequently, the threshold for 
hypoxia will vary from organ to organ (Vaupel, 1990). Nevertheless, radiosensitivity 
decreases rapidly for oxygen tensions (pO2) lower than 10 mmHg, as illustrated in Figure 
5. The oxygen tension of 10 mmHg is therefore often used as a threshold value for 
hypoxia. The biological damage produced by ionizing radiation comes from two different 
actions: direct and indirect, the latter of which demands oxygen in order to fully take 
effect. Direct action of radiation is seen when the radiation interacts directly with the 
DNA strand, while indirect action occurs when the radiation interacts with other atoms or 
molecules in the cell to produce free radicals. Free radicals can react with oxygen to 
create a peroxide form, which is a non-restorable form. The oxygen is thought to “fix” the 
damage so that it is irreparable. The indirect damage is responsible for approximately two 
thirds of the total damage when using X-rays, resulting in a diminished effect of the 
radiation where oxygen is lacking. The oxygen enhancement ratio (OER) is defined as the 
ratio of radiation doses under hypoxic to normoxic conditions required to obtain the same 
biological effect. For X-rays and gamma rays, the OER of high radiation doses has a 
value between 2.5 and 3.5 (Hall and Giaccia, 2006).  
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Figure 5: Idealized representation of the relationship between relative radiosensitivity and 
oxygen tension. The figure is reproduced from Hall and Giaccia (2006).  
 
In addition, when the pO2 levels are below 10 mmHg, cells increase their 
production of genes regulated by hypoxia inducible factor 1 (HIF-1) (Dewhirst et al., 
2008). HIF-1 activation promotes the transcription of many genes that code for proteins 
involved in angiogenesis, glucose metabolism, cell proliferation, and metastasis 
(Semenza, 2003). Furthermore, overexpression of HIF-1Į has been found in a wide range 
of human tumors and their metastases (Zhong et al., 1999). HIF-1 is an oxygen-sensitive 
transcriptional factor (Ke and Costa, 2006). Under hypoxic conditions, HIF-1Į proteins 
translocate to the nucleus where they heterodimerize with HIF-1ȕ proteins, forming the 
heterodimer HIF-1. Active HIF-1 then binds to distinct DNA sequences within hypoxia-
response elements (HRE) and begins to transactivate specific target genes (Leo et al., 
2004). Under normoxic conditions, HIF-1Į is degraded (Ke and Costa, 2006).  
Low levels of oxygen prevent cells from being killed by radiation; therefore, 
tumors with a significant amount of hypoxic cells are resistant to radiation therapy 
(Brown, 1999). Additionally, hypoxic cells in tumors are resistant to several anticancer 
drugs. This resistance is caused by various reasons, including the hindering of drug 
delivery and the hypoxic status affecting the toxicity of the drug (Brown and Wilson, 
2004). Furthermore, a clinical study by Höckel et al. (1993) on patients with cancer of the 
uterine cervix has shown that patients with hypoxic tumors (Median pO210 mmHg) have 
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a lower probability of both survival and recurrence-free survival than patients with non-
hypoxic tumors, regardless of which standard treatment the patients are receiving. The 
probability of recurrence-free survival is shown in Figure 6 (Höckel et al., 1993). Similar 
results have also been presented for head and neck cancer and soft tissue sarcoma (Brizel 
et al., 1999; Nordsmark et al., 2001; Nordsmark and Overgaard, 2000). 
 
 
Figure 6: Probability of recurrence-free survival among patients with advanced cancer of the 
uterine cervix and median tumor pO2 higher or lower than 10 mmHg. The median pO2 level was 
determined prior to treatment by using Eppendorf probes. The figure is reproduced from Höckel 
et al. (1993). 
  
There is a wide range of methods for determining the existence and/or extent of 
tumor hypoxia. These methods include radiobiological assays, pimonidazole experiments, 
oxygen electrodes, magnetic resonance imaging (MRI) techniques (e.g., blood-oxygen-
level-dependent (BOLD) contrast), electron paramagnetic resonance (EPR), positron 
emission tomography (PET), and single photon emission spectroscopy (SPECT) 
(Hoogsteen et al., 2007; Horsman, 1998; Tatum et al., 2006; Vaupel and Mayer, 2007). 
There is currently no gold standard when it comes to measuring tumor hypoxia (Tatum et 
al., 2006). Every method has its advantages and limitations, and before attempting to 
measure hypoxia one should carefully consider the purpose of the measurement 
(Horsman, 1998). 
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Several strategies to combat hypoxia-related problems in cancer treatment have 
been suggested. These strategies include radiosensitizers, hyperthermic treatments, 
hyperbaric oxygen, nicotinamide and structurally related analogs, antiangiogenic drugs, 
accelerated fractionated radiotherapy combined with hyperoxic carbogen gas and 
nicotinamide (ARCON), bioreductive drugs, and gene therapy (Brown, 1999; Hoogsteen 
et al., 2007; Horsman, 1995; Wouters et al., 2002).  
Interstitial fluid pressure 
Most experimental and human tumors show increased interstitial fluid pressure 
(IFP) compared to normal tissue; measurements as high as 100 mmHg have been 
recorded in tumors (Heldin et al., 2004; Lunt et al., 2008). IFP is strictly controlled in 
normal tissue and is normally close to atmospheric levels (0 mmHg) (Lunt et al., 2008). 
The main driving force for elevated IFP in tumors is the hydrostatic microvascular 
pressure (MVP) (Boucher et al., 1990; Boucher and Jain, 1992). The abnormal 
vasculature in tumors results in increased geometric resistance to vascular blood flow, 
and the high vessel permeability in tumors allows fluid to flow easily from the 
vasculature into the interstitium. As a result, the MVP forces fluid from the vasculature 
into the tumor interstitium. In normal tissue, excessive fluid is drained away by the 
lymphatic system, but most tumors lack a functioning lymphatic system (Padera et al., 
2002). Consequently, fluid accumulates in the interstitium, expands the elastic 
extracellular matrix, and causes interstitial hypertension (Milosevic et al., 1999).  
Preclinical studies have shown that tumor IFP is uniform throughout the center of 
the tumor and decreases drastically at the rim of the tumor (Boucher et al., 1990; Rofstad 
et al., 2002b). A characteristic experimental tumor IFP profile is shown in Figure 7. 
Clinical studies, however, have suggested some spatial heterogeneity within central parts 
of the tumor (Milosevic et al., 1998).  
IFP is a reflection of the global pathophysiology and may, therefore, have value as 
a biomarker for diagnosis and/or prognosis (Fukumura and Jain, 2007). Furthermore, 
there is no general correlation between tumor IFP and oxygenation, even though tumor 
IFP is inversely correlated to oxygenation in some tumors (Boucher et al., 1995). Several 
studies suggest that high IFP in the tumor is correlated with poor prognoses (Heldin et al., 
2004). This has been seen in a study of patients with cervical cancer, where the 
recurrence rate was higher in patients with primary tumors with high IFP (Fyles et al., 
2006). Furthermore, preclinical studies have suggested that elevated IFP is associated 
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with pulmonary and lymph node metastasis independent of hypoxia, and with poor 
radiocurability (Rofstad et al., 2002b; Rofstad et al., 2009; Rofstad et al., 2010b). 
 
 
Figure 7: IFP profile of human melanoma xenografts. IFP is measured from the tumor rim. 
Individual points refer to the means of six tumors, and bars represent the standard error. The 
figure is reproduced from Rofstad et al. (2002b). 
 
Elevated IFP in tumors can compromise the delivery of blood-borne therapeutic 
agents to tumors (Fukumura and Jain, 2007; Heldin et al., 2004; Lunt et al., 2008). 
Therapeutics move from the vasculature into the interstitium, either by diffusion or by 
convection (Lunt et al., 2008). Compounds with high molecular weight are mainly 
transported by convection, whereas compounds of lower molecular weight are transported 
by diffusion (Heldin et al., 2004; Lunt et al., 2008). High IFP in tumors limits or even 
eliminates the pressure gradient across the vessel wall, thus hindering the uptake of some 
cancer drugs. In addition, the pressure gradient in the periphery of the tumor may force 
drugs already in the interstitium out of the tumor. 
Extracellular pH 
Intracellular pH (pHi) in tumors is neutral or alkaline, whereas extracellular pH 
(pHe) is acidic. The result is a reversed pH gradient across the tumor-cell plasma 
membrane (pHi>pHe) in tumors compared to normal tissue, where pHe is higher than pHi 
(Stubbs et al., 2000). There are several reasons for low pHe in tumors, one of them being 
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the altered glucose metabolism in tumors, which results in high lactic acid production. 
Another reason for the extracellular acidity is the increased level of carbonic acid. 
Insufficient drainage due to the lack of a functioning lymphatic system in tumors leads to 
an accumulation of protons, hence a lower pHe (Fukumura and Jain, 2007; Vaupel, 2004). 
A preclinical study has shown that pHe decreases with increasing distance from the 
nearest blood vessel, as presented in Figure 8. Additionally, the same study demonstrated 
that there is no general spatial correlation between low pHe and hypoxia (Helmlinger et 
al., 1997). 
 
Figure 8: Mean interstitial pO2 and mean extracellular pH as a function of distance from the 
nearest blood vessel. Open squares: pHe. Closed triangles: pO2. The figure is reproduced from 
Helmlinger et al. (1997). 
 
Studies on human melanoma xenografts have suggested that acidic pHe may 
increase the invasiveness and the angiogenic potential of tumor cells, and promote 
metastasis (Rofstad et al., 2006). In addition, clinical studies on human cervical 
carcinoma and head and neck tumors have shown that high lactate levels in the primary 
tumor are associated with a high risk of metastatic growth (Walenta et al., 1997; Walenta 
et al., 2000). Furthermore, acidic pHe can affect the outcome of therapy because the 
reversed pH gradient in tumors hinders the uptake of basic drugs, and may increase the 
uptake of acidic drugs (Tredan et al., 2007). 
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Metastases 
More than 90% of cancer-related deaths can be attributed to metastases (Wirtz et 
al., 2011). In order to establish distant metastases there are several steps in the metastatic 
process that have to be completed (Fidler, 1978; Steeg, 2006; Wirtz et al., 2011). 
Understanding the process leading to distant metastasis is, therefore, important. This 
chapter will give an overview of the metastatic process and the impact the physiological 
microenvironment of the primary tumor may have on the metastatic process.  
The metastatic process 
The most important and most common routes of metastatic dissemination involve 
dissemination by the blood vessels and/or lymphatics (Poste and Fidler, 1980). Among 
the tumor cells that reach the circulatory system, only 0.1% are able to survive and 
complete the metastatic process (Fidler et al., 1978). Lymph node metastasis and 
hematogenous metastasis can be driven by distinctly different mechanisms; however, 
several steps in the metastatic process are similar. An overview of the metastatic process 
is presented in Figure 9.  
The process starts with the establishment and vascularization of the primary 
tumor. The vasculature provides the tumor with oxygen and nutrients, as well as 
facilitating the invasion of cancer cells into the blood vessels. Lymphangiogenesis may 
start simultaneously with the angiogenesis, and can be driven by some of the same growth 
factors (Cao, 2005; Wong and Hynes, 2006). Several studies have shown increased 
numbers of lymphatics surrounding growing tumors; however, the existence of a 
functioning lymphatic system within the tumor is debated (Cao, 2005; Wong and Hynes, 
2006). In either case, the existence of both peritumoral and intratumoral lymphatics has 
been positively correlated with lymphatic metastasis (Cao, 2005).  
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Figure 9: The metastatic process. In order to develop distant metastases, several steps have to be 
fulfilled. The figure is reproduced from Fidler (1978).  
 
To be able to metastasize, cancer cells must detach from the primary tumor and 
invade blood vessels or lymphatics. The process of detachment and invasion can be either 
passive, where the cells are shed from the primary tumor, or active, by directed migration 
(Wong and Hynes, 2006). The transport of cancer cells is not necessarily carried out 
exclusively by the lymphatics or by the vasculature; cancer cells may begin to be 
disseminated in the lymphatics and then transported into the vasculature. During 
transport, the cancer cells may experience interactions, such as aggregation with other 
tumor cells, platelets, lymphocytes, and other host cells (Fidler, 1978). Furthermore, 
cancer cells transported by blood vessels can experience serum toxicity, high shear 
stresses, and mechanical deformation. Cancer cells traveling by the lymphatics have some 
advantages over those in the blood circulation because the smallest lymphatic vessels are 
larger than the blood capillaries, and the flow velocities in the lymphatics are orders of 
magnitude lower than those in the blood vessels. Furthermore, lymphatic vessels are filled 
with interstitial fluid, which promotes tumor cell viability (Pepper et al., 2003). Cancer 
cells traveling in clusters are more likely to establish metastasis than cells traveling alone. 
Additionally, it has been suggested that cancer cells bringing stromal components, 
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including fibroblasts, from the primary tumor, also increase their probability of 
successfully establishing distant metastases (Duda et al., 2010).  
Cancer cells in the lymphatic system are first carried to the regional lymph nodes 
where they may proliferate; regional lymph nodes are therefore a common site for the 
initial spread of cancer. Cancer cells in the blood stream tend to be arrested in capillary 
beds, then penetrate the walls of these tiny vessels, and finally invade the surrounding 
tissue. Because of the blood-flow pattern, cancer cells usually meet their first capillary 
beds in the lungs; the lungs are thus a frequent site for metastases (Becker et al., 2006). 
The growth of a new tumor in a secondary organ is considered to be the most challenging 
step which cancer cells meet during the metastatic process (Chambers et al., 1995). 
There are two different theories regarding which distant organ cancer cells in the 
circulatory system settle will in: the seed and soil hypothesis, and the 
anatomical/mechanical hypothesis. The seed and soil hypothesis was established in 1889 
by Stephen Paget, who examined postmortem data from women with breast cancer and 
realized that the organ distribution of metastases in the patients was non-random. He 
suggested, therefore, that some tumor cells (the “seeds”) prefer certain organs (the “soil”) 
(Paget, 1989). The mechanical/anatomical theory postulates that it is the anatomy of the 
vasculature and lymphatic drainage from the site of the primary tumor that determines the 
pattern of the metastases. Today it is believed that the two theories are not mutually 
exclusive and that their influence depends on the primary tumor investigated (Langley 
and Fidler, 2011).  
The tumor microenvironment and metastatic disease 
The metastatic process is most likely not random since the cancer cell has to 
acquire a range of properties to be able to fulfill all the steps of the process (Woodhouse 
et al., 1997). Moreover, the microenvironment of the primary tumor may contribute to the 
regulation of cell phenotype, and might therefore have an impact on the malignant 
progression (Rofstad, 2000; Subarsky and Hill, 2003). Several studies, both clinical and 
preclinical, have shown that hypoxia, acute and chronic, affects the extent of metastasis 
(Brizel et al., 1996; Cairns et al., 2001; Rofstad et al., 2010a; Young et al., 1988). It has 
also been shown that pHe influences the extent of metastasis (Jang and Hill, 1997; 
Rofstad et al., 2006). Fewer studies have evaluated the relationship between elevated IFP 
and metastasis; however, some studies have shown that elevated IFP increases the 
probability of metastasis (Milosevic et al., 2001; Rofstad et al., 2002b). 
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Acquisition of the necessary traits for a cell to metastasize may arise from the 
accumulation of specific mutations and/or transient changes in gene expression. These 
genes code for proteins which may be utilized by the cancer cell at different steps in the 
metastatic process. These steps include angiogenesis, invasion/migration, and survival 
(Subarsky and Hill, 2003). Examples of such proteins involved at different steps of the 
metastatic process are VEGF, which is involved in angiogenesis, and urokinase-type 
plasminogen activator receptor (uPAR), which is involved in invasion and migration. 
Both of these have been associated with hypoxia and increased metastatic efficiency in 
human melanoma xenografts (Rofstad et al., 2002a; Rofstad and Danielsen, 1999). 
DCE-MRI  
In DCE-MRI, a contrast agent (CA) is injected intravenously, and a series of MR 
images is recorded before and during uptake of the CA in the tissue so that the change in 
signal intensity with time can be recorded for each voxel (Yankeelov and Gore, 2009). 
Uptake of the CA in the tissue is determined by several physiological parameters such as 
blood flow, vessel wall permeability, surface area of the capillaries, cell density, and 
extracellular volume fraction (ECVF) (Taylor et al., 1999; Weinmann et al., 1984). 
CAs used in MRI are designed to increase the difference in signal intensity 
between different tissues. CAs change the inherent proton density of the tissue and/or the 
relaxation rates and, consequently, the MR signal from the tissue. Most CAs are designed 
to alter the longitudinal (T1) and/or transversal (T2) relaxation times. CAs that decrease T1 
cause a signal intensity increase in T1-weighted images; therefore, these agents are often 
referred to as positive relaxation agents. CAs decreasing T2, on the other hand, are often 
called negative relaxation agents because the T2 reduction results in a signal intensity 
decrease in a T2-weighted image (Yankeelov and Gore, 2009). Techniques where T2 
weighting is used in DCE-MRI are often referred to as dynamic susceptibility contrast 
magnetic resonance imaging (DSC-MRI).  
Gd-DTPA is one of the most commonly used CAs. It is a stable paramagnetic 
complex with a molecular weight of about 550 Da; it is distributed extracellularly, is 
rapidly excreted from the body, and is generally well tolerated (Weinmann et al., 1984). 
A paramagnetic CA such as Gd-DTPA increases the contrast between different tissues by 
decreasing T1 and T2. The magnitude of the effect of Gd-DTPA on the two different 
relaxation times is dependent on the concentration of Gd-DTPA. At low concentrations, 
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the T1-relaxation-rate will be significantly more decreased than the T2-relaxation-rate, 
whereas at high concentrations, mainly the T2-relaxation-rate will be decreased (Hendrick 
and Haacke, 1993).  
DCE-MRI data acquisition for quantitative analysis 
To perform quantitative analysis of DCE-MRI data, three steps have to be taken 
during the DCE-MRI data acquisition. First of all, a method is needed to determine the 
concentration of the CA in the tissue. One method is T1 mapping, which demands several 
T1-weighted images taken at different flip angles. This method assumes a linear 
relationship between signal intensity increase and the concentration of the CA 
(Yankeelov and Gore, 2009). Another method is that used by Hittmair et al. (Hittmair et 
al., 1994). This method requires proton density images and the use of phantoms with 
known concentrations of the CA. 
 Secondly, several T1-weighted images have to be taken before and after 
administration of the CA.  
Thirdly, knowledge about the concentration of the CA in the arteries as a function 
of time, often referred to as the arterial input function (AIF), is necessary for almost all 
quantitative DCE-MRI data analysis (Yankeelov and Gore, 2009). There are several ways 
to measure the AIF; the methods either involve individual measurements or assume that 
the AIF is similar for all subjects. Individual measurements can be taken by obtaining the 
AIF from the DCE-MRI dataset by measuring the uptake in a large arterial vessel within 
the field of view of the DCE-MRI uptake, or by introducing an arterial catheter into the 
subject and sampling the blood during the measurements. The advantage of the first 
method is its noninvasiveness, while the disadvantage is the demand for a large arterial 
vessel within the image and the restrictions that this implies. Laboratory mice have a total 
blood volume of approximately 2 ml, so when working with them it is difficult to 
withdraw the required number of blood samples. By assuming a similar AIF for all 
subjects, it is only necessary to perform blood measurements on a cohort of subjects and 
then assume that the resulting average AIF is valid for subsequent studies. The advantage 
of using a common AIF is that no more AIF measurements are required during the DCE-
MRI imaging. The method ignores any variation in the injection rate and differences in 
AIF between individuals (Yankeelov and Gore, 2009). 
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Quantitative analysis of DCE-MRI data 
Quantitative analyses are based on fitting the DCE-MRI data to mathematical 
models. The most elementary quantitative model describes the body as one compartment; 
the CA enters the compartment with a volume V, at a specific rate constant ka, and is 
eliminated with a rate constant ke. Normally, CAs are distributed at different rates in 
different tissues, and these kinetics are, therefore, better described by a two-compartment 
model (Yankeelov and Gore, 2009). In a two-compartment model, such as the one shown 
in Figure 10, the blood plasma is considered as one compartment and the extravascular 
extracellular space (EES) as the other. The CA enters the capillary and either remains in 
the capillary or extravasates to the EES.  
 
 
Figure 10: Illustration of the uptake of a CA in tissue. Ktrans is the volume transfer constant of the 
CA. The CA does not enter the intracellular space; hence ve is the extravascular extracellular 
volume fraction. The figure is reproduced from Jackson et al. (2007). 
 
In 1999, several experts in the field of MR tracer kinetic models published a 
paper, in which they developed a generalized pharmacokinetic model, referred to as the 
generalized kinetic model of Tofts (Tofts et al., 1999):  
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where Ct (T) is the concentration of the CA in the tissue at time T after injection; Ktrans is 
the transfer constant of the CA; Hct is the hematocrit; Ca(Ĳ) is the concentration of the CA 
in the arteries at time Ĳ (Ca(Ĳ) is the arterial input function); and ve is the extravascular 
extracellular volume fraction. 
In addition to the assumption that the body consists of two compartments, the 
generalized kinetic model of Tofts also assumes that the CA is uniformly distributed in 
each compartment. Tofts’ model is normally used as described in Eq. 1, with knowledge 
about the AIF and by calculating the CA-concentration from signal intensity, as for 
instance described by Hittmair et al. (1994). Another well-known two-compartment 
model is the Brix model, which most commonly does not make use of T1 mapping, 
calculation of concentration from signal intensity (the use of phantoms), or AIF. This 
model is often used by calculating the relative signal intensity in each voxel, and not by 
calculating the concentration change in each voxel, which is common when one uses the 
model of Tofts.  
Semiquantitative analyses and visual inspection 
In addition to the quantitative approach to DCE-MRI, visual inspection and 
semiquantitative analyses can be carried out. Visual inspection is a subjective evaluation 
of the shapes of the time-signal intensity curves (Yankeelov and Gore, 2009). 
Semiquantitative analyses are less demanding than quantitative analysis, but are not as 
subjective as the methods where visual inspection is used. Parameters from 
semiquantitative analysis include the initial area under the curve (iAUC), the time to peak 
(TTP), and the slope of the washout curve. However, the physiological meaning of 
parameters derived from semiquantitative analysis is ambiguous. In addition, because 
semiquantitative analyses are based on signal intensity methods, the measurements can be 
influenced by scanner settings. Studies done at different times or at different institutions 
are therefore difficult to compare (Paldino and Barboriak, 2009; Yankeelov and Gore, 
2009). The advantage of these methods, on the other hand, is that they are easily 
implemented, and several studies have successfully monitored cancer growth and 
treatment response by employing them (Yankeelov and Gore, 2009).  
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EXPERIMENTAL 
METHODS 
The main methods used in this research are briefly summarized below. More 
detailed descriptions can be found in Papers I-VI. 
 
Melanoma lines 
Six human melanoma lines (A-07, C-10, D-12, R-18, U-25, V-27), grown either 
intradermally (i.d.) or intramuscularly (i.m.) in the legs of athymic mice, were used as 
tumor models for human melanomas. Two human cervix carcinoma lines (CK-160, TS-
415), grown intramuscularly (i.m.), were used as tumor models of human cervix 
carcinomas. These tumor lines are permanent cell lines at our laboratory, and are 
described in detail elsewhere (Ellingsen et al., 2009; Rofstad, 1994; Rofstad and 
Mathiesen, 2010).  
 
Tumor vasculature and connective tissue 
Tumor microvasculature was studied by examining histological sections prepared 
from tumor tissue frozen in liquid nitrogen. The sections were immunostained for blood 
vessels or connective tissue by using a peroxidase-based indirect staining method. An 
anti-mouse CD31 rat monoclonal antibody (Research Diagnostics, Flanders NJ) or an 
anti-collagen rabbit polyclonal antibody (Dako, Glostrup, Denmark) was used as the 
primary antibody.  
 
Tumor oxygen tension 
Tissue pO2 was measured simultaneously at two positions in each tumor using a 
fiber optic oxygen-sensing device (Oxylite 2000, Oxford Optronix, Oxford, U.K.). The 
pO2 traces were subjected to detailed analysis. Thus, for each pO2 trace, the fluctuation 
frequency (i.e., the number of pO2 fluctuations per hour) around the mean pO2 of the 
trace, and the amplitudes of the fluctuations were calculated by using the definitions and 
methods described elsewhere (Brurberg et al., 2004).  
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Irradiation 
Tumors were irradiated in vivo under air-breathing or hypoxic conditions. An X-
ray unit operated at 220 kV, 19-20 mA, and with 0.5-mm Cu filtration was used. The dose 
rate given to the xenografted tumors was 5.1 Gy/min.  
 
Cell survival assay 
Cell survival was measured in vitro using a plastic surface colony assay (Rofstad 
et al., 2007). Cells which gave rise to colonies >50 cells were scored as clonogenic. The 
cell-surviving fraction of a tumor given a single dose of irradiation was calculated from 
the plating efficiency of the cells of the irradiated tumors and the mean plating efficiency 
of six untreated control tumors. The cell-surviving fraction of a tumor given fractionated 
radiation treatment was corrected for the cell yields of the irradiated tumor and the six 
control tumors. In other words, the surviving fraction was measured relative to the 
number of clonogenic cells in the tumors right before the first radiation exposure 
(Rofstad, 1989).  
 
Hypoxia 
The fraction of radiobiological hypoxic cells (HFRad) was found by using the 
paired survival curve method, and the fraction of pimonidazole hypoxic cells (HFPim) was 
assessed in histological sections prepared from tumors fixed in phosphate-buffered 4% 
paraformaldehyde embedded in paraffin. The fractions of chronically hypoxic cells 
(HFChr) and acutely hypoxic cells (HFAcu) were calculated from the fraction of 
radiobiological hypoxic cells (HFRad) and the fraction of pimonidazole-positive hypoxic 
cells (HFPim) as HFChr=HFPim and HFAcu=HFRad-HFChr (Rofstad and Måseide, 1999). 
 
Lymph node metastases 
The mice were euthanized immediately after DCE-MRI and irradiation, and then 
examined for external lymph node metastasis in the inguinal, axillary, interscapular, and 
submandibular regions, and for internal lymph node metastases in the abdomen and 
mediastinum.  
 
Pulmonary metastases 
Microscopic pulmonary metastases were detected by histological examination. 
Resected lungs were fixed in phosphate-buffered 4% paraformaldehyde and embedded in 
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paraffin. Histological sections were cut from each lobe at 100-ȝm intervals and stained 
with hematoxylin and eosin. Groups of five or more tumor cells were scored as a 
metastasis. 
 
DCE-MRI and kinetic modeling 
DCE-MRI was performed on a clinical 1.5 T whole body scanner (Signa, General 
Electric, Milwaukee, WI, U.S.A.) with a cylindrical slotted tube resonator transceiver coil 
specially constructed for mice (Rofstad et al., 1994; Seierstad et al., 2007). The animals 
were put on an adapted cradle of Styrofoam before being inserted into the coil to prevent 
excessive heat loss. In addition, a thermostatically regulated heating pad was used to 
maintain the temperature of the animal at 37-38°C while scanning. Two calibration tubes 
were placed adjacent to the animal in the coil, one with 0.5 mmol/L Gd-DTPA (Schering, 
Berlin, Germany) in 0.9% saline and the other with 0.9% saline. Firstly, a sagittal scan 
was used to localize the tumor, and to decide the position of the single axial section 
through the tumor, which was used during the rest of the scanning. An image matrix of 
256×128, a field of view of 8×4 cm2, and one excitation were used. 
T2-weighted images were recorded by using a spin echo sequence with TR = 5000 
ms and TE = 65 ms, followed by two proton density images (TR = 900 ms, TE = 3.2 ms, 
and Įpd = 20°). Then three T1-weighted images (TR = 200 ms, TE = 3.2 ms, and ĮT1 = 
80°) were recorded before Gd-DTPA was administered. The Gd-DTPA was diluted in 
0.9% saline to a concentration of 0.06 M and administered into the tail vein of the mice in 
a bolus dose of 5.0 mL/kg (i.e., 0.3 mmol/kg), corresponding to an injection volume of 
0.12-0.15 mL. The administration was performed manually during a period of 5 s by 
using a 24G-neoflon connected to a syringe by polyethylene tubing. Following the 
injection, T1-weighted images were recorded for 15 minutes. The spatial resolution was 
0.31×0.31×2.0 mm3, and the time resolution was 14 s. 
Using the method of Hittmair et al., the tissue concentrations of Gd-DTPA were 
calculated from the increase in signal intensities (Hittmair et al., 1994). The DCE-MRI 
series was then analyzed by using the arterial input function of Benjaminsen et al. 
(Benjaminsen et al., 2004) and the Tofts pharmacokinetic model (Tofts et al., 1999). The 
image analyses were performed using in-house developed software in IDL (Interactive 
Data Language). Parametric images of Ktrans and ve were generated with SigmaPlot 
software (SPSS Science, Chicago, IL, U.S.A.).  
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SYNOPSIS OF RESULTS 
I. The pO2 fluctuation pattern and cycling hypoxia in human cervical carcinoma and 
melanoma xenografts.  
The purpose of this study was to investigate whether tumors of different histological 
types differ in pO2 fluctuation pattern and extent of acute and chronic hypoxia. Cervical 
carcinomas CK-160 and TS-415, and melanomas A-07 and R-18 xenografts were 
included in the study. The microvasculature was investigated by histological 
examinations, and the results showed that the cervical carcinoma tumors had a higher 
fraction of connective tissue-associated blood vessels than the melanoma tumors. 
Furthermore, tissue pO2 was measured in the tumors at two positions by using an Oxylite 
fiber optic oxygen-sensing device. In addition, the extent of acute and chronic hypoxia 
was assessed by combining a radiobiological and a pimonidazole-based 
immunohistochemical assay of tumor hypoxia. The temporal heterogeneity in tissue pO2 
was larger in the melanoma xenografts than in the cervical carcinoma xenografts. 
Moreover, the ratio of the fraction of acutely hypoxic cells to the fraction of chronically 
hypoxic cells (HFAcu/HFChr) was higher in intradermal melanoma xenografts than in 
intramuscular cervical carcinoma xenografts.  
 
II. Differentiation between hypoxic and non-hypoxic experimental tumors by dynamic 
contrast-enhanced magnetic resonance imaging. 
To evaluate whether tumor hypoxia can be assessed by DCE-MRI, three tumor 
models without hypoxic tissue (small A-07 i.d., small A-07 i.m., and small R-18 i.d.) and 
three with hypoxic regions (large A-07 i.d., large A-07 i.m., and large R-18 i.d.) were 
subjected to DCE-MRI. The hypoxic statuses of the tumor models were determined by 
using a radiobiological assay and a pimonidazole-based immunohistochemical assay. 
Median Ktrans was significantly higher in the non-hypoxic tumors; however, median ve 
was not able to differentiate the hypoxic tumors from the non-hypoxic tumors. In 
addition, tumor response to fractionated radiation was measured by giving fractions of 2 
Gy six times in 60 hours. The surviving fractions were significantly higher in the hypoxic 
tumors than in the non-hypoxic tumors. 
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III. Assessment of hypoxia and radiation response in intramuscular experimental 
tumors by dynamic contrast-enhanced magnetic resonance imaging.  
Previous studies in our laboratory have suggested that DCE-MRI-derived parameters 
may provide valuable information about the extent of hypoxia in intradermal melanoma 
xenografts (Egeland et al., 2006; Egeland et al., 2008). In another previous study in our 
laboratory, it was shown that similar median Ktrans and median ve in intramuscular and 
intradermal tumors reflected different radiobiological hypoxic fractions (Gulliksrud et al., 
2010). This study, therefore, investigated whether DCE-MRI has the potential for 
assessing the extent of tumor hypoxia in intramuscular melanoma xenografts. R-18, V-27, 
and U-25 intramuscular melanoma xenografts were subjected to DCE-MRI and then 
irradiated with a single dose of 10 Gy for determination of the radiobiological hypoxic 
fraction (HFRad). Median Ktrans decreased with increasing HFRad, and the correlation was 
similar for the three tumor cell lines. Median ve correlated with the surviving fraction after 
10 Gy, but did not correlate with HFRad.  
 
IV. Assessment of tumor responsiveness and metastatic potential by dynamic contrast-
enhanced magnetic resonance imaging. 
In this study we investigated whether DCE-MRI can be used to assess radiation 
resistance and metastatic potential. R-18 tumors grown intramuscularly were subjected to 
DCE-MRI followed by irradiation with either a single fraction of 10 Gy for detection of 
radiobiological hypoxia, or five fractions of 4 Gy in 48 hours to evaluate the 
radioresponsiveness. Finally, the host mice were euthanized before examination of lymph 
node metastases. Hypoxic tumors had lower median Ktrans than non-hypoxic tumors. 
Furthermore, Ktrans decreased with the increasing surviving fraction after fractionated 
radiation. Tumors in metastasis-positive mice had lower median Ktrans than tumors in 
metastasis-negative mice. However, there was no significant correlation between median 
ve and tumor hypoxia, radioresponsiveness, or metastatic potential.  
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V. Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential 
of tumors: A preclinical study of cervical carcinoma and melanoma xenografts.  
To further investigate the potential of DCE-MRI for assessing metastatic potential, 
intramuscularly implanted CK-160 cervical carcinomas and V-27 melanoma tumors were 
used as tumor models. The tumors were first subjected to DCE-MRI; immediately 
afterwards, the host mice were euthanized before examination of lymph node metastasis. 
Highly metastatic tumors showed lower values for median Ktrans than poorly metastatic 
tumors in both tumor models. Median ve was lower for highly metastatic than for poorly 
metastatic V-27 tumors, but did not differ significantly for CK-160 tumors.  
 
VI. Dynamic contrast-enhanced magnetic resonance imaging of the hypoxia-associated 
metastatic potential of human melanoma xenografts.  
In Papers IV and V, the potential of DCE-MRI to provide information about the 
metastatic potential of tumors was investigated in intramuscular melanoma and cervical 
carcinoma xenografts which metastasized to the lymph nodes. In this study, we extended 
the analysis to intradermal melanoma xenografts and investigated the potential of DCE-
MRI to provide biomarkers for hematogenous metastatic dissemination. C-10 and D-12 
xenografts were subjected to DCE-MRI, followed by resection of the primary tumor and 
the lungs, which were prepared for histological assessment of the fraction of hypoxic cells 
and the presence of lung metastases. The primary tumors of the metastasis-positive mice 
had higher HFPim values, lower values of median Ktrans, and lower values of ve than the 
metastasis-negative mice.  
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DISCUSSION 
Evaluation of methods 
Relevance of tumor models  
Human melanoma and cervix carcinoma xenografts grown intradermally (i.d.) or 
intramuscularly (i.m.) in athymic mice were used as models for human cancer in the 
current study. Cervical carcinoma xenografts were exclusively grown intramuscularly. 
Xenografted human tumors generally maintain many of the biological characteristics of 
the original human tumor (Sutherland et al., 1988). Studies of A-07, D-12, R-18, and U-
25 tumors implanted orthotopically have shown that they retain the histological 
appearance, the microvessel density and ultrastructure, the angiogenic potential, the 
treatment response, and the organ-specific metastatic pattern of the original tumor 
(Rofstad, 1994). All melanoma cell lines used in this study mirror the aggressiveness of 
the donor patient’s tumor when implanted orthotopically (Rofstad and Mathiesen, 2010). 
Examinations of the cervical carcinoma cell lines CK-160 and TS-145 have shown that, 
when they are grown intramuscularly, they have the same histological pattern, radiation 
sensitivity, and metastatic pattern of the original tumor (Ellingsen et al., 2009).  
Several studies have suggested that animal models using orthotopically implanted 
tumors are more predictive of responses to therapeutics in the clinic than ectopically 
implanted tumors. Furthermore, orthotopic implantation is considered to be necessary for 
an accurate analysis of tumor growth and metastasis (Killion et al., 1998; Talmadge et al., 
2007). However, studies where the same human cancer cell lines were implanted in 
different organs suggest that the vascularization and perfusion in the tumors will differ 
between the organs (Bernsen et al., 1999). Previous DCE-MRI studies in our laboratory 
have mainly been carried out on intradermal melanoma xenografts (Egeland et al., 2006; 
Egeland et al., 2008; Egeland et al., 2012). In the current study, we wanted to challenge 
the general validity of previous observations by studying intramuscular melanoma 
xenografts. 
Paper I investigated whether the pO2 fluctuation pattern and the extent of cycling 
hypoxia differ between tumor types showing high and low fractions of connective tissue-
associated blood vessels. Two melanoma lines (A-07 and R-18) and two cervical 
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carcinoma lines (CK-160 and TS-415) were included in the study. These tumor models 
were selected for the study because the tumor microvessels in cervical carcinoma are 
located within broad bands of connective tissue, whereas microvessels in melanomas are 
not.  
The main purpose of the study presented in Paper II was to investigate whether 
DCE-MRI has the potential to distinguish tumors with hypoxia from tumors without 
hypoxia. Six different tumor models were included in the study: small A-07 i.d., A-07 
i.m., and R-18 i.d.; and large A-07 i.d., A-07 i.m., and R-18 i.d. tumors. The small tumors 
developed either no or an insignificant amount of tumor hypoxia, whereas all large 
tumors developed hypoxia. The development of tumor hypoxia depends on a range of 
factors such as the vascularity of the surrounding tissue, the potential of tumor cells to 
synthesize and secrete angiogenic factors, and the respiratory activity of the tumor cells 
and, hence, the cell density of the tumor tissue (Gillies et al., 1999; Gulledge and 
Dewhirst, 1996; Moulder and Rockwell, 1984). The chosen tumor models in Paper II 
show significant differences in cell density, secretion of IL-8 and VEGF A, and 
expression of PDGF and basic fibroblast growth factor (bFGF) (Egeland et al., 2009; 
Rofstad and Halsør, 2000; Vestvik et al., 2007). 
Preliminary investigations have suggested that R-18, U-25, and V-27 are 
melanoma lines in which differences between intradermal and intramuscular tumors are 
particularly large. Intramuscularly injected R-18, U-25, and V-27 tumors were therefore 
chosen as tumor models in Paper III, since the main goal of the study was to investigate 
the potential of DCE-MRI in assessing tumor hypoxia in intramuscular melanoma 
xenografts.  
Papers IV, V, and VI investigated whether low values of the DCE-MRI-derived 
parameters Ktrans and ve can be associated with metastatic potential. Tumor models 
included in these studies have all shown the ability to metastasize in previous studies in 
our laboratory (Ellingsen et al., 2009; Rofstad, 1994; Rofstad and Mathiesen, 2010). 
Furthermore, the metastatic potential is associated with hypoxia for some of the tumor 
models. Tumor hypoxia in R-18 (Paper IV) promotes lymph node metastasis by 
upregulating the expression of uPAR (Rofstad et al., 2002a). Tumor hypoxia in C-10 and 
D-12 (Paper VI), on the other hand, promotes lung metastases by upregulating the 
proangiogenic factors IL-8 and VEGF-A (Rofstad and Halsør, 2002; Rofstad and 
Mathiesen, 2010). Additionally, it has been shown that lymph node metastases in CK-160 
(Paper V) tumors are associated with the fraction of hypoxic cells in the primary tumor 
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(Ellingsen et al., 2012). These tumor models are therefore particularly interesting for 
investigating the value that DCE-MRI has as a biomarker for metastatic potential, 
especially since it has been suggested that their metastatic efficiency is closely related to 
hypoxia.  
It has been claimed that acutely hypoxic cells have higher metastatic potential 
than chronically hypoxic cells (Rofstad et al., 2007). The results from Paper I suggest that 
the temporal heterogeneity in tissue pO2 and the fraction of hypoxic cells showing cycling 
hypoxia are larger in melanomas than in cervical carcinomas. In Paper V, cervical 
carcinoma CK-160 and melanoma V-27 tumors were used as tumor models. By including 
these models, it was possible to verify the validity of our DCE-MRI method both for 
tumors with a large degree of fluctuations in pO2 and for tumors with a small degree. 
Anesthesia and temperature effects 
All experiments were carried out on anesthetized animals. An anesthetic 
consisting of fentanyl citrate, fluanisone, and midazolane was used. The use of this 
particular anesthetic may lead to a drop of 2-3°C in the body temperature if no 
precautions are taken. Such a drop in temperature is undesirable in this study as it may 
affect blood flow, consequently possibly affecting oxygenation. In order to avoid 
temperature drops in our experiments, heating pads and isolating materials were used. 
When maintaining the temperature, it has been verified that the anesthesia does not alter 
the tumor blood perfusion significantly (Gulliksrud et al., 2009). 
Invasive measurements of tumor hypoxia 
In the current study, three different invasive measurements of hypoxia were used: 
Oxylite probe measurements, the paired survival curve method, and 
immunohistochemistry with pimonidazole. The first method is the only one that 
determines oxygen partial pressure (pO2), whereas the other two determine the fraction of 
hypoxic cells in a tumor.  
Oxylite measurements 
Oxylite measurements were used in Paper I to investigate whether fluctuation 
patterns differ among tumors of different histological types. The use of Oxylite 
measurements has some disadvantages. One of these is that measuring with probes makes 
it is difficult to know whether the measurements are taken in viable or necrotic tissue 
(Horsman, 1998). In order to avoid measurements in necrotic tissue in the current study, 
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the probes were positioned in tumor regions showing pO2 values clearly higher than 0 
mmHg. Another disadvantage of using the Oxylite system is that it provides poor spatial 
resolution; movements of the probes induce tissue trauma, which can influence the 
oxygen tension. Previous experiments in our laboratory have shown that, by excluding the 
first 20 minutes of the Oxylite measurements, artificially induced pO2 fluctuations due to 
the insertion of the probes are avoided (Brurberg et al., 2005). Advantages of using 
Oxylite include high sensitivity in the hypoxic regions and excellent temporal resolution 
(Griffiths and Robinson, 1999).  
Assessment of radiobiological hypoxic fraction (HFRad) 
The classic methods of estimating tumor hypoxia are based on radiation response. 
The three typical assays for assessing HFRad in animal systems are the paired survival 
curve method, tumor growth delay assay, and local tumor control assay (Horsman, 1998; 
Moulder and Rockwell, 1984). Of these three methods, the paired survival curve method 
is the most commonly used (Hall and Giaccia, 2006) and was indeed used in the current 
study. 
There are both advantages and disadvantages to using a radiobiological assay for 
determining the fraction of hypoxic cells in a tumor. First of all, the fraction of 
radiobiological hypoxic cells is determined at the time the irradiation is given; therefore, 
radiobiological assays can not provide knowledge about the temporal kinetics associated 
with acute hypoxia. Secondly, information about the spatial distribution of the hypoxic 
cells in the tumor is lost in the paired survival curve method because the tumor is minced 
immediately after irradiation. However, when assessing the radiobiological hypoxic 
fraction, both chronic and acute hypoxia are detected (Fenton et al., 1995). Furthermore, 
the radiobiological hypoxic fraction is considered to be of greater clinical importance than 
hypoxic fractions derived from non-radiobiological assays, as only clonogenic cells are of 
relevance for tumor growth and response to treatment.  
Assessment of pimonidazole-positive hypoxic fraction (HFPim) 
Pimonidazole can be used to detect various subpopulations of hypoxic cells. The 
concentration of pimonidazole injected, how it is injected, the time from injection to 
resection of the tumor, and the technique for producing the immunohistochemical 
preparations determine which subpopulation it measures (Gulliksrud et al., 2008). A 
pimonidazole assay which mainly measures chronically hypoxic cells has been 
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established in our laboratory (Rofstad and Måseide, 1999), and this assay was used in the 
current study.  
Immunohistochemical assays do not distinguish between clonogenic and 
nonclonogenic cells. However, previous studies have shown a significant correlation 
between the radiobiological hypoxic fraction (HFRad) and the pimonidazole-positive 
hypoxic fraction (HFPim) in our melanoma xenografts (Egeland et al., 2012). Unlike 
radiobiological assays, this assay also provides spatial information about the hypoxic 
regions of the tumor (Fenton et al., 1995).  
Calculating the fraction of acutely hypoxic cells from HFRad and HFPim 
In the current study, we used the pimonidazole assay to measure chronically 
hypoxic cells; the fraction of chronically hypoxic cells (HFChr) is therefore equal to the 
fraction of pimonidazole-positive cells (HFPim). The fraction of acutely hypoxic cells 
could therefore be determined by the following equation: HFAcu= HFRad-HFPim (Rofstad 
and Måseide, 1999). Our definition of chronic and acute hypoxia is based on the 
assumption that the clonogeneity of chronically hypoxic cells is equal to the clonogeneity 
of the normoxic and acutely hypoxic cells. However, it has been suggested that the 
clonogeneity of chronically hypoxic cells is lower than that of normoxic cells (Fenton et 
al., 1995). Furthermore, this calculation assumes that the radiobiological hypoxic fraction 
and the immunohistochemical hypoxic fraction appear at the same oxygen tensions. This 
is not completely true, as immunohistochemical hypoxia appears at tensions below 10 
mmHg, while 50% radiosensitivity occurs at pO2 of 3.0 mmHg. In addition, it has been 
suggested that chronically hypoxic cells can be more sensitive to radiation than acutely 
hypoxic cells (Rofstad et al., 1999). Consequently, the fraction of acutely hypoxic cells 
may have been underestimated in this study (Paper I).  
Radiation response assays 
In Papers II and IV, the tumor response to fractionated radiation was measured in 
vitro using a clonogenic assay. The total dose of radiation was 12 Gy (6×2 Gy) in Paper II 
and 20 Gy (5×4 Gy) in Paper IV. It should be noted that clinically relevant treatment 
regimes would probably consist of approximately five and three times larger radiation 
doses, respectively. The use of a larger radiation dose than those employed in this study 
would probably result in a very low number of clonogenic cells and therefore lead to 
increased uncertainty. In addition, the clinical treatment regimes are given over a longer 
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period of time than in the studies reported herein. The surviving fractions were measured 
relative to the number of clonogenic cells in the tumors immediately before the first 
radiation exposure. Therefore, an extension of the treatment time would increase the 
uncertainty of the measurement. There are two other relevant assays that could have been 
considered instead of the cell survival assay. These are the tumor growth delay (TGD) 
and the tumor control (TCD50) assays. Our experience with the TGD assay and large 
radiation doses is that the results have a higher uncertainty than those of the cell survival 
assay. In our study we wanted to look at individual tumors, and the tumor control assay 
(TCD50) studies groups of animals, rather than individual tumors.  
Detection of lymph node metastases 
In the current study, the lymph node was scored as metastasis-positive when it 
was enlarged. Histological examinations previously performed in our laboratory have 
demonstrated that enlarged lymph nodes in melanoma xenografts contain metastatic 
deposits (Rofstad et al., 2002). There are, however, better methods for detecting lymph 
node metastases. One option could be to use cells transfected with green fluorescent 
protein (GFP); by doing so, the presence of micrometastases could be detected by 
studying the lymph nodes using a fluorescence microscope. This way, metastatic deposits 
which had not yet enlarged the lymph node would not be mistakenly characterized as 
metastasis-negative. However, a disadvantage is the possibility of detection of clusters of 
cells or even single cells that will not proliferate in the new location and establish a new 
tumor. By looking at enlarged lymph nodes, only cells that have grown in the new 
location are scored as metastasis positive.  
Acquisition and analysis of DCE-MRI 
MR-scanner and MR-coil 
All MR-imaging in the current study was performed with a 1.5 T clinical whole 
body scanner. MR-imaging of the physiology in small tumors, such as the imaging 
performed in this study, is demanding, because high spatial resolution is necessary. In 
order to improve the signal to noise ratio (SNR), a small inductive coupled capacitive 
overlap transmit-receiver MR-coil specially designed for mice was used (Seierstad et al., 
2007). The coil provides an adequate SNR for the spatial and temporal resolutions used in 
this study (Benjaminsen et al., 2004; Brurberg et al., 2007). An advantage of using a 
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clinical scanner is that it makes the possible transition from an animal MR procedure to a 
clinical MR procedure easier. 
Limitations in the acquisition of the DCE-MRI series 
Two significant limitations of the DCE-MRI study are the use of manual injection 
rather than the use of an infusion pump, and the use of a mean AIF instead of individual 
AIFs. Manual injection of a CA may lead to some variation among individuals; however, 
by using mean AIF, these variations are ignored. The mean AIF used in this study was 
determined previously by sampling blood from 12 mice and determining the 
concentration of Gd-DTPA by using MRI. Individual AIFs of three mice were compared 
to the mean AIF. The individual AIFs did not differ significantly from each other, or from 
the mean AIF (Benjaminsen et al., 2004). The mice used in this study have identical 
genetic backgrounds, which makes the use of a mean AIF valid. Moreover, the 
reproducibility of our DCE-MRI procedure was examined by imaging the same tumors 
twice within an interval of three hours. The resulting parametric images were found to be 
almost identical (Benjaminsen et al., 2004). The gain from using an infusion pump or 
individual AIFs would therefore probably be limited. Nevertheless, in a clinical setting, 
individual AIFs would be necessary due to the expected interpatient variability.  
Furthermore, only one axial slice through the tumor was scanned in the DCE-MRI 
experiments. However, analysis of the results from a previous study in our laboratory, 
where a slice-interleaving acquisition method was used to cover the entire tumor, showed 
similar results in the parametric distribution from the entire tumor as for those derived 
from one axial slice (Gaustad et al., 2005). Therefore, it is unlikely that the results 
reported here would have been different if the entire tumor volume had been scanned 
instead of only one slice.  
Correction for tumor necrosis 
In the present study, the generalized kinetic model of Tofts was used to analyze 
the recorded DCE-MRI data. This model is based on material conservation and assumes 
equilibrium between the extracellular volume fraction (ECVF) and the blood. In necrotic 
tumor regions the assumption of equilibrium does not hold. The generalized kinetic 
model of Tofts is therefore not valid for necrotic tissue. Previous studies have 
demonstrated that, for all orthotopically implanted melanoma xenografts used in our 
laboratory, threshold values for ve can be used to exclude voxels with nonphysiological ve 
values (Egeland et al., 2012). Furthermore, significant correlations have been found 
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between the fraction of necrotic voxels assessed by our DCE-MRI method and the 
fraction of necrotic tissue assessed by histological examination (Egeland et al., 2008; 
Egeland et al., 2011). Consequently, voxels showing nonphysiological ve values were 
excluded from the Ktrans and ve frequency distribution of the tumors. However, for the 
CK-160 tumors used in Paper V, it is not possible to differentiate between viable and 
necrotic tissue by using ve with the spatial resolution that we have used. This is probably 
because the voxels consist of a mixture of different tissues (Ellingsen et al., 2010) 
Observations in perspective  
Assessment of tumor hypoxia by DCE-MRI 
Tumor hypoxia results from an imbalance between the demand for and supply of 
oxygen (Gulledge and Dewhirst, 1996). Hypoxia is, therefore, expected to be found in 
regions with low blood perfusion and/or high cell density (i.e., low ECVF) (Jain, 1988; 
Vaupel, 1990). The DCE-MRI-derived parameters Ktrans and ve are assumed to represent 
blood perfusion and the extracellular volume fraction, respectively, in tumors showing 
high transvascular permeability to Gd-DTPA (Tofts et al., 1999). It has been established 
that, for our DCE-MRI procedure, these assumptions are valid for intradermally 
implanted A-07, D-12, R-18, and T-22 tumors (Egeland et al., 2009). It can therefore be 
hypothesized that low Ktrans and/or ve values would be a characteristic feature of hypoxic 
tumors.  
The potential that Ktrans and ve may have in separating hypoxic from non-hypoxic 
tumors was investigated by using the following tumor models: A-07 i.d. (Paper II), R-18 
i.d. (Paper II), A-07 i.m. (Paper II), and R-18 i.m. (Paper III). Ktrans was significantly 
lower for hypoxic tumors than for non-hypoxic tumors for all the investigated tumor 
models. It was not possible, on the other hand, to make any distinction between hypoxic 
and non-hypoxic tumors with respect to ve. Furthermore, the capability of our DCE-MRI 
method to determine the extent of tumor hypoxia was investigated in intramuscular R-18, 
U-25, and V-27 tumors (Paper III), and in intradermal C-10 and D-12 tumors (Paper VI). 
Ktrans decreased with increasing hypoxic fraction for all the investigated tumor models. 
Additionally, ve decreased with increasing hypoxic fraction for intradermal C-10 and D-
12 tumors (Paper VI). The results confirm our expectations and are in accord with the 
hypothesis. 
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 Ktrans was related to the hypoxic status for all the tumor models used in the current 
study. This might imply that poor oxygen supply is the most important factor for hypoxia 
in the investigated tumor models. Additionally, ve was related to hypoxia for intradermal 
C-10 and D-12 tumors (Paper VI), suggesting that, for these tumor models, the oxygen 
consumption also has a significant impact on the development of hypoxia in the tumor.  
A study performed in our laboratory showed that Ktrans and ve decrease with 
increasing hypoxic fraction for eight different intradermal melanoma tumor models 
(Egeland et al., 2012). The results obtained in the current study are thus consistent with 
the study by Egeland et al. (2012). Furthermore, this study is an extension of the previous 
study because it includes intramuscularly implanted melanomas as well as intradermally 
implanted melanomas. Even though similar trends for Ktrans and ve have been shown for 
detecting the hypoxic fraction in intradermal and intramuscular tumors, it has been 
suggested that quantitative assessment of tumor hypoxia by DCE-MRI may require the 
use of tumor site-specific criteria when translating DCE-MRI data into hypoxic fractions 
(Gulliksrud et al., 2010).  
Several clinical studies have also suggested that valid information about the 
hypoxic status may be obtained by using DCE-MRI. Cooper et al. (2000) used Eppendorf 
probes to measure tumor oxygenation in 30 patients with cervical carcinoma; DCE-MRI 
was performed prior to obtaining oxygenation data. Tumor oxygenation levels were found 
to correlate with their semiquantitative DCE-MRI-derived parameters (Cooper et al., 
2000). Loncaster et al. (2002) also investigated the relationship between hypoxia and 
DCE-MRI-derived parameters for patients with carcinoma of the cervix. The study also 
used Eppendorf probes to measure tumor oxygenation; however, it used a 
pharmacokinetic model, the Brix model, and a semiquantitative analysis of the DCE-MRI 
data. Both semiquantitative and quantitative parameters correlated with tumor 
oxygenation. Newbold et al. (2009) examined whether there was a relationship between 
DCE-MRI-derived parameters and intratumoral hypoxia in seven patients with head and 
neck cancer. In that study, pimonidazole and CA9 staining were used as markers for 
hypoxia. Also in that study, they chose to analyze the data both semiquantitatively and 
quantitatively. Quantitatively, their analyses were performed by using a model similar to 
that of Tofts’. Their Ktrans and ve both correlated with hypoxia. However, contrary to our 
results, Ktrans in that study increased with increasing degree of hypoxia. This can be 
explained by the fact that their Ktrans values represent the leakiness of the vessels in the 
tumors, whereas Ktrans for our tumor models represents blood perfusion. ve, on the other 
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hand, as in our study, decreased with increasing degree of hypoxia and represented EES 
(Newbold et al., 2009). As in our study, these clinical studies have shown correlations 
between hypoxia in tumors and DCE-MRI-derived data. Taken together, these studies 
strongly suggest that DCE-MRI may be a useful method for identifying tumors with poor 
oxygenation. 
Assessment of radiation response by DCE-MRI 
Radiation resistance in tumors is closely related to hypoxia, and the current study has 
shown that DCE-MRI can be a valuable tool for detecting hypoxia in tumors. The 
potential that Ktrans and ve might have as predictive markers for response to fractionated 
radiation was therefore investigated for intradermal A-07 and R-18 tumors (Paper II), and 
intramuscular A-07 (Paper II) and R-18 (Paper IV) tumors. These studies showed that 
Ktrans decreased with increasing surviving fraction. These results suggest that DCE-MRI 
has potential as a predictive tool for the outcome of fractionated radiation. 
This suggestion is in agreement with several clinical studies (Zahra et al., 2007). 
Loncaster et al. (2002) had 50 cervical carcinoma patients that underwent DCE-MRI 
before being given radiotherapy. Their DCE-MRI data were analyzed both 
semiquantitatively and quantitatively; only one of the pharmacokinetic parameters 
(amplitude (A)) showed a statistically significant correlation with disease-specific 
survival (Loncaster et al., 2002). Semple et al. (2009) investigated whether DCE-MRI 
could predict outcome for patients with locally advanced cervical carcinoma treated with 
chemoradiation. Interestingly, they found a correlation between Ktrans and clinical 
response (Semple et al., 2009). Yuh et al. (2009) investigated whether they could use 
DCE-MRI to predict control of the primary tumor and survival for patients with cervical 
cancer. They performed DCE-MRI before and twice during the radiation therapy course. 
The results from the DCE-MRI taken before treatment showed no correlation with control 
of the primary tumor or disease-free survival; however, there were some statistically 
significant correlations for the DCE-MRI-derived parameters from the DCE-MRI 
recordings during the course of treatment and control of the primary tumor and disease-
free survival. Their data were analyzed semiquantitatively (Yuh et al., 2009). Zahra et al. 
(2009) analyzed data from just 13 patients with cervical cancer and found a correlation 
between both semiquantitatively derived parameters and quantitatively derived 
parameters, and tumor regression after radiotherapy. The most interesting result in that 
study was probably the correlation found between Ktrans and tumor regression (Zahra, 
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2009). Semple et al. (2009) and Zahra et al. (2009) found that Ktrans increased with 
increased response to treatment, which is consistent with our results. Direct comparisons 
of our results to those found in studies with semiquantitative analyses, are difficult 
because these parameters often have other physiological meanings than ours, or even an 
unclear physiological meaning. Furthermore, the correlations found in some of these 
clinical studies are also often generally weak; possibly the analysis was semiquantitative. 
Nevertheless, these studies do show a correlation between DCE-MRI-derived parameters 
and the outcome of radiotherapy. Consequently, this preclinical study can be seen as an 
extension of the existing clinical studies, and it warrants further clinical investigation. We 
will, however, based on the results of our study, recommend the use of pharmacokinetic 
models where Ktrans and ve are the derived parameters.  
Assessment of metastatic potential by DCE-MRI 
It has been demonstrated that hypoxia can promote metastasis (Brizel et al., 1996; 
Cairns et al., 2001; Rofstad et al., 2010a; Young et al., 1988). Furthermore, it has been 
suggested that cyclic hypoxia might be more important for the promotion of metastasis 
than chronic hypoxia (Dewhirst 2009; Rofstad, 2000). In the current work, we have 
shown that Ktrans and ve can give valuable information about the hypoxic fraction in the 
primary tumor. We therefore hypothesized that DCE-MRI would show promise as a 
biomarker for metastatic potential for tumors, in which hypoxia promotes the metastatic 
disease. We have shown that intramuscular R-18 (Paper IV), V-27 (Paper V), CK-160 
(Paper V), and intradermal C-10 (Paper VI) and D-12 (Paper VI) tumors in metastasis-
positive mice have significantly lower Ktrans values than tumors in metastasis-negative 
mice. Furthermore, intradermal C-10 and D-12 tumors (Paper VI) in metastasis-positive 
mice have a significantly lower ve than those in metastasis-negative mice. The results 
meet the expectation of the hypothesis. 
In Paper V, CK-160 cervical carcinoma and V-27 melanoma xenografts were used 
as tumor models to investigate the potential that DCE-MRI might have in distinguishing 
between poorly and highly metastatic tumors. It has been shown that melanoma 
xenografts exhibit more cyclic hypoxia than do cervical carcinoma xenografts (Paper I). 
The DCE-MRI results from Paper V suggest that our DCE-MRI method works equally 
well for tumors with a lot of cyclic hypoxia, as for tumors with little cyclic hypoxia.  
The draining lymphatics were investigated in Paper V, where it was discovered 
that they were enlarged in animals showing metastasis-positive inguinal lymph nodes. 
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This suggests that tumor hypoxia promotes lymphogenous metastatic spread by 
upregulating pro-lymphangiogenic factors. Several studies of different tumor types have 
shown correlations between tumor hypoxia, expression of the pro-lymphangiogenic factor 
vascular endothelial growth factor C (VEGF-C), lymphangiogenesis, and lymph node 
metastasis (Chaudary et al., 2011; Min et al., 2011; Schoppmann et al., 2006).  
To our knowledge, there is only one other preclinical study so far which has 
investigated the usefulness of DCE-MRI as a biomarker for metastatic potential. The 
study, done by Li et al. (2007), used xenografted tumors of two melanoma lines 
transplanted subcutaneously into athymic mice. The tumors were subjected to 
gadodiamide-based DCE-MRI. It was shown that Ktrans was significantly lower in the 
most metastatic line (C8161) compared to the least metastatic line (A375P). This result 
was consistent with the histological observation showing that the density of functional 
blood vessels was higher in the least metastatic line than in the most metastatic line. 
However, only three tumors of the most metastatic line and four of the least metastatic 
line were included. Also, the metastatic potential was based on historical information 
rather than on the metastatic status of the host. In addition, the differences in Ktrans 
between the two lines were limited to the core of the tumors, and it was necessary to 
analyze the DCE-MRI data by the fast exchange regime-permitted model, a 
pharmacokinetic model incorporating the effects of transcytolemmal water exchange. 
Nevertheless, it was concluded that DCE-MRI may provide potential biomarkers for the 
metastatic potential in tumors (Li et al., 2007). This is strongly supported by the present 
study. Furthermore, in the current study, a large number of tumors was used. In addition, 
the differences in Ktrans and ve were found for the center as well as for the rim of the 
tumor, and the metastatic status of the tumor host was used to determine metastatic 
potential. Moreover, the analysis of the DCE-MRI data was performed by a relatively 
simple pharmacokinetic model, which has been recommended by both the US National 
Cancer Institute and the Pharmacokinetic Technologies Advisory Committee of Cancer 
Research UK for analysis of DCE-MRI data in clinical trials of anticancer therapeutics 
affecting tumor vascularization (Leach et al., 2003). 
 Several clinical studies have investigated the potential that DCE-MRI may have 
in predicting lymph node status, recurrence, or metastasis for breast cancer patients. Bahri 
et al. (2008) analyzed DCE-MRI data from 62 patients both semiquantitatively and 
pharmacokinetically by using the Tofts model. They found significant correlations 
between DCE-MRI-derived parameters and lymph node status at the time of the DCE-
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MRI recording, and between the DCE-MRI parameters and recurrence after 
approximately five years (Bahri et al., 2008). Hsiang et al. (2007) recorded DCE-MRI 
data from 46 patients with locally advanced breast cancer receiving neoadjuvant 
chemotherapy. After the chemotherapy, the patients underwent mastectomy and 
lumpectomy, and axillary lymph node dissection. It was shown that the result from DCE-
MRI can be predictive of the axillary nodal status after neoadjuvant chemotherapy 
(Hsiang et al., 2007). Loiselle et al. (2011) analyzed their DCE-MRI data from 167 
patients semiquantitatively and found a significant difference in peak enhancement 
between patients who were lymph node positive and patients who were lymph node 
negative (Loiselle et al., 2011). Tuncbilek et al. (2011) investigated the relationship 
between DCE-MRI semiquantitative parameters and recurrence or metastasis for 49 
patients with breast cancer. Two of the DCE-MRI parameters (maximal enhancement 
ratio within the first minute (Emax/1) and steepest slope) showed a statistically significant 
difference between patients with regard to recurrence or metastases (Tuncbilek et al., 
2011). These studies differ in the choice of analysis method of the DCE-MRI data by 
using either semiquantitative or quantitative analysis of the DCE-MRI data.  
Nevertheless, all the studies have concluded that DCE-MRI-derived parameters from the 
primary tumor can be used as a predictive marker of lymph node status, metastasis, or 
recurrence for breast cancer patients. Together with the present preclinical study, this 
calls for further clinical investigations of the potential that DCE-MRI may have as a 
biomarker for metastatic potential. 
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CONCLUSIONS 
 
Gd-DTPA-based DCE-MRI has been shown to provide valuable information 
about the existence as well as the extent of hypoxia in tumors. 
 
The tumor response to radiation therapy may be predicted by the use of Gd-
DTPA-based DCE-MRI.  
 
Reliable information about metastatic potential can be obtained by Gd-DTPA-
based DCE-MRI.  
 
This preclinical study has used a well-known pharmacokinetic model in order to 
analyze the recorded DCE-MRI data. The results show convincing and statistically strong 
correlations with hypoxia, radiation response, and metastatic potential. We will therefore 
recommend the use of pharmacokinetic models in future clinical studies. 
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APPENDIX 
ABBREVIATIONS AND SYMBOLS 
 
AIF  arterial input function 
CA  contrast agent 
DCE-MRI dynamic contrast enhanced magnetic resonance imaging 
EC  endothelial cell 
ECVF  extracellular volume fraction 
EES  extravascular extracellular space 
FGF  fibroblast growth factor 
Gd-DTPA gadolinium diethylene-triamine penta-acetic acid 
HFAcu  fraction of acutely hypoxic cells 
HFChr  fraction of chronically hypoxic cells 
HFPim  fraction of pimonidazole-positive cells 
HFRad  fraction of radiobiologically hypoxic cells 
HIF  hypoxia inducible factor 
i.d.  intradermal 
IFP  interstitial fluid pressure 
IL-8  interleukin 8 
i.m.  intramuscular 
Ktrans the volume transfer constant (min-1) of the contrast agent between blood 
plasma and the extravascular extracellular space 
MVP microvascular pressure 
OER  oxygen enhancement ratio 
PDGF  platelet-derived growth factor  
pHi  intracellular pH 
pHe  extracellular pH 
pO2  oxygen tension 
SNR  signal to noise ratio 
TCD50  the dose at which 50% of the tumors are locally controlled 
TGD  tumor growth delay 
 60
uPAR  urokinase-type plasminogen activator receptor 
ve  the fractional distribution volume of the contrast agent 
VEGF  vascular endothelial growth factor  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I

II

III

IV

V

VI

